knowledge -WSS

knowledge

author：leisure time 2025-09-29 20:52:17 - browse：8

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： FTC loses bid to block Novant's North Carolina hospital merger

WSS

Addiction experts warn against a second 'war on drugs'

A new initiative will help leaders fight the next pandemic

Data integrity in scientific journals requires "effort" by publishers, institutions

Senators tussle over abortion against the backdrop of a presidential campaign

How CO2 helps viruses stay alive longer in the air

Senators tussle over abortion against the backdrop of a presidential campaign

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Activists slam private health insurers over coverage restrictions

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Apple is now the first public company to be valued at $3 trillion

An outdated Medicare rule harms dementia patients with anxiety

Trump demands the U.S. pay no more for drugs than other countries … again

Take antibiotics after sex, CDC recommends for certain risk groups

As demand for Covid shots wanes, Moderna seeks its next success

Venture capitalist Bob Kocher on the state of digital health

Continuity nursing helped my family in our darkest PICU moments

Venture capitalist Bob Kocher on the state of digital health

hotspot

Helping hospitals and community health centers plan for resilience

Venture capitalist Bob Kocher on the state of digital health

FDA approves Moderna’s RSV vaccine, its second licensed product

CMS got Medicare Advantage quality rating wrong, judge rules

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Wearables generate powerful data but its not useful to doctors, yet

hotspot

entertainment

hotspot

focus